Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

For years, medtech companies have treated the digital experience around their devices as an afterthought. A layer of software ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) pricing in Medicare Part B in court, accusing it of government overreach. The ...

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such announcement since cases of the infection started to surge around the start ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...